Metabolites in modern medicine: Decoding the future of Health and diseases

Year : 2024 | Volume : | : | Page : –
By

B. Harshitha,

Ashwini V,

Fazeela Mahaboob Begum S.M,

  1. Student School of Life sciences, B S Abdur Rahman crescent Institute of Science and technology Chennai India
  2. Student School of Life sciences, B S Abdur Rahman crescent Institute of Science and technology Chennai India
  3. Assistant Professor School of Life sciences, B S Abdur Rahman crescent Institute of Science and technology Chennai India

Abstract

The end products of many metabolic processes in cells are called metabolites. Each reaction contributes a specific metabolite. Metabolites act as fingerprints of on-going biological processes. Constant changes in cellular composition due to both environmental and internal factors. By analysing the types and presence of metabolites, Scientists can effectively reconstruct the inner workings of a cell or organism. In the past, analysing metabolites was a slow and tedious process, often limited to measuring a small number of known metabolites. As technology advances, the development of new analytical tools has made metabolic profiling convenient by screening thousands of metabolites simultaneously. By analysing changes in metabolite profiles, we can identify the effects of environmental contaminants on organisms. As the downstream products of gene expression and environmental interactions, metabolites serve as valuable biomarkers for various diseases. With their ability to predict treatment response, diagnose diseases earlier, and improve patient outcomes, metabolite biomarkers hold great promise to revolutionize the healthcare profession. By identifying unique metabolic fingerprints researchers can stratify patients into subgroups with distinct disease trajectories and treatment responses. Metabolomics is being used to develop personalized therapies that will improve patient outcomes and reduce side effects. Advances in technology of metabolomics paves a way for its integration into the clinical practices. This promises a future where diseases can be prevented, diagnosed, and treated, leading to improved health and longevity. This review highlights the metabolome’s significance as a tool for understanding cellular function and disease. It also explores the application of metabolomics in various fields of biology and medicine.

Keywords: Metabolites, metabolic profile, biomarkers, cellular function, disease, environmental contaminants

How to cite this article: B. Harshitha, Ashwini V, Fazeela Mahaboob Begum S.M. Metabolites in modern medicine: Decoding the future of Health and diseases. Emerging Trends in Metabolites. 2024; ():-.
How to cite this URL: B. Harshitha, Ashwini V, Fazeela Mahaboob Begum S.M. Metabolites in modern medicine: Decoding the future of Health and diseases. Emerging Trends in Metabolites. 2024; ():-. Available from: https://journals.stmjournals.com/etm/article=2024/view=167775

References

  1. Putri SP, Yamamoto S, Tsugawa H, Fukusaki E. Current metabolomics: Technological advances. J Biosci Bioeng. 2013;116(1):9–16.
  2. Patti GJ, Yanes O, Siuzdak G. Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13(4):263–9.
  3. Liu X, Locasale JW. Metabolomics: A Primer. Trends Biochem Sci. 2017;42(4):274–84.
  4. Pang H, Hu Z. Metabolomics in drug research and development: The recent advances in technologies and applications. Acta Pharm Sin B. 2023;13(7):3238–51.
  5. Gonzalez-Covarrubias V, Martínez-Martínez E, del Bosque-Plata L. The potential of metabolomics in biomedical applications. Metabolites. 2022;12(2):194.
  6. Nalbantoglu S. Metabolomics: basic principles and strategies. Mol Med. 2019;10(1).
  7. Agin A, Heintz D, Ruhland E, de La Barca JC, Zumsteg J, Moal V, et al. Metabolomics–an overview. From basic principles to potential biomarkers (part 1). Med Nucl. 2016;40(1):4–10.
  8. Hollywood K, Brison DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics. 2006;6(17):4716–23.
  9. Ryan D, Robards K. Metabolomics: The greatest omics of them all? Anal Chem. 2006;78(23):7954–8.
  10. Segers K, Declerck S, Mangelings D, Heyden YV, Eeckhaut AV. Analytical techniques for metabolomic studies: A review. Bioanalysis. 2019;11(24):2297–318.
  11. Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst. 2005;130(5):606–25.
  12. Reo NV. NMR-based metabolomics. Drug Chem Toxicol. 2002;25(4):375–82.
  13. Nagana Gowda GA, Raftery D. Recent advances in NMR-based metabolomics. Anal Chem. 2017;89(1):490–510.
  14. Markley JL, Brüschweiler R, Edison AS, Eghbalnia HR, Powers R, Raftery D, et al. The future of NMR-based metabolomics. Curr Opin Biotechnol. 2017;43:34–40.
  15. Emwas AHM, Salek RM, Griffin JL, Merzaban J. NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. Metabolomics. 2013;9(5):1048–72.
  16. Vinaixa M, Schymanski EL, Neumann S, Navarro M, Salek RM, Yanes O. Mass spectral databases for LC/MS-and GC/MS-based metabolomics: State of the field and future prospects. TrAC Trends Anal Chem. 2016;78:23–35.
  17. Fancy SA, Rumpel K. GC-MS-based metabolomics. Biomark Methods Drug Discov Dev. 2008;317–40.
  18. Beale DJ, Pinu FR, Kouremenos KA, Poojary MM, Narayana VK, Boughton BA, et al. Review of recent developments in GC–MS approaches to metabolomics-based research. Metabolomics. 2018;14(12):1–31.
  19. Zhou B, Xiao JF, Tuli L, Ressom HW. LC-MS-based metabolomics. Mol BioSyst. 2012;8(2):470–81.
  20. Fang ZZ, Gonzalez FJ. LC–MS-based metabolomics: an update. Arch Toxicol. 2014;88(9):1491–502.
  21. Lu W, Bennett BD, Rabinowitz JD. Analytical strategies for LC–MS-based targeted metabolomics. J Chromatogr B. 2008;871(2):236–42.
  22. van de Velde B, Guillarme D, Kohler I. Supercritical fluid chromatography–Mass spectrometry in metabolomics: Past, present, and future perspectives. J Chromatogr B. 2020;1161:122444.
  23. Shulaev V, Isaac G. Supercritical fluid chromatography coupled to mass spectrometry–A metabolomics perspective. J Chromatogr B. 2018;1092:499–505.
  24. Chen L, Dean B, Liang X. A technical overview of supercritical fluid chromatography-mass spectrometry (SFC-MS) and its recent applications in pharmaceutical research and development. Drug Discov Today Technol. 2021;40:69–75.
  25. Ramautar R, Somsen GW, de Jong GJ. CE‐MS in metabolomics. Electrophoresis. 2009;30(1):276–91.
  26. Çelebier M, Nenni M. Recent developments in CE-MS based metabolomics. Curr Anal Chem. 2021;17(9):1229–42.
  27. Soga T. Advances in capillary electrophoresis mass spectrometry for metabolomics. TrAC Trends Anal Chem. 2023;158:116883.
  28. Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):132.
  29. Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819–75.
  30. Li ZB, Liu J, Zhang SQ, Yu Y, Liang HF, Lu QQ, et al. Novel potential metabolic biomarker panel for early detection of severe COVID-19 using full-spectrum metabolome and whole-transcriptome analyses. Signal Transduct Target Ther. 2022;7(1):129.
  31. Perazzoli G, García-Valdeavero OM, Peña M, Prados J, Melguizo C, Jiménez-Luna C. Evaluating metabolite-based biomarkers for early diagnosis of pancreatic cancer: a systematic review. Metabolites. 2023;13(7):872.
  32. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134(5):714–7.
  33. Metwaly A, Reitmeier S, Haller D. Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nat Rev Gastroenterol Hepatol. 2022;19(6):383–97.
  34. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016;15(7):473–84.
  35. Jacob M, Lopata AL, Dasouki M, Abdel Rahman AM. Metabolomics toward personalized medicine. Mass Spectrom Rev. 2019;38(3):221–38.
  36. Amaro F, Carvalho M, Bastos MDL, Guedes de Pinho P, Pinto J. Pharmacometabolomics applied to personalized medicine in urological cancers. Pharmaceuticals. 2022;15(3):295.
  37. Baraldi E, Carraro S, Giordano G, Reniero F, Perilongo G, Zacchello F. Metabolomics: moving towards personalized medicine. Ital J Pediatr. 2009;35(1):1–4.
  38. Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One. 2012;7(7)
  39. Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, et al. Metabolomics enables precision medicine: “a white paper, community perspective”. Metabolomics. 2016;12(10):1–15.
  40. Rahman M, editor. Metabolomics: A Path Towards Personalized Medicine. Academic Press; 2023.
  41. Koen N, Du Preez I, Loots DT. Metabolomics and Personalized Medicine. In: Personalized Medicine. Academic Press; 2016. p. 53–78.
  42. Thorburn AN, Macia L, Mackay CR. Diet, Metabolites, and “Western-Lifestyle” Inflammatory Diseases. Immunity. 2014;40(6):833–42.
  43. Bonvallot N, David A, Chalmel F, Chevrier C, Cordier S, Cravedi JP, et al. Metabolomics as a powerful tool to decipher the biological effects of environmental contaminants in humans. Curr Opin Toxicol. 2018;8:48–56.
  44. Chen L, Zhernakova DV, Kurilshikov A, Andreu-Sánchez S, Wang D, Augustijn HE, et al. Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome. Nat Med. 2022;28(11):233
  45. Bundy JG, Davey MP, Viant MR. Environmental metabolomics: A critical review and future perspectives. Metabolomics. 2009;5:3-21.
  46. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009;15(2):431-40.
  47. Qaderi MM, Martel AB, Strugnell CA. Environmental factors regulate plant secondary metabolites. Plants. 2023;12(3):447.
  48. Kim CH. Immune regulation by microbiome metabolites. Immunology. 2018;154:220-9.
  49. Levy M, Blacher E, Elinav E. Microbiome, metabolites and host immunity. Curr Opin Microbiol. 2017;35:8-15.
  50. Shtossel O, Koren O, Shai I, Rinott E, Louzoun Y. Gut microbiome-metabolome interactions predict host condition. Microbiome. 2024;12(1):24.
  51. Wu J, Wang K, Wang X, Pang Y, Jiang C. The role of the gut microbiome and its metabolites in metabolic diseases. Protein Cell. 2021;12:360-73.
  52. La Barbera L, Rizzo C, Grasso G, Macaluso F, Camarda F, Ciccia F, Guggino G. The cross-talk between microbiome and metabolome in rheumatoid arthritis. BioChem. 2023;3(1):47-60.
  53. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabolomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002;1(2):153-61.
  54. Peregrín-Alvarez JM, Sanford C, Parkinson J. The conservation and evolutionary modularity of metabolism. Genome Biol. 2009;10:1-17.
  55. Suhre K, editor. Genetics meets metabolomics: from experiment to systems biology. Springer Science & Business Media; 2012.
  56. Smoleńska Ż, Zdrojewski Z. Metabolomics and its potential in diagnosis, prognosis and treatment of rheumatic diseases. Reumatologia. 2015;53(3):152-6.
  57. Zhang A, Sun H, Wang X. Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal Bioanal Chem. 2012;404:1239-45.
  58. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910-4.
  59. Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism with cancer. J Clin Invest. 2013;123(9):3652-8.
  60. Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X, et al. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 2021;503:240-8.
  61. Yoon H, Shaw JL, Haigis MC, Greka A. Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity. Mol Cell. 2021;81(18):3708-30.
  62. Liu J, Mazzone PJ, Cata JP, Kurz A, Bauer M, Mascha EJ, Sessler DI. Serum free fatty acid biomarkers of lung cancer. Chest. 2014;146(3):670-9.
  63. Lane AN, Fan TW. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015;43(4):2466-85.
  64. Di Minno A, Gelzo M, Caterino M, Costanzo M, Ruoppolo M, Castaldo G. Challenges in metabolomics-based tests, biomarkers revealed by metabolomic analysis, and the promise of the application of metabolomics in precision medicine. Int J Mol Sci. 2022;23(9):5213.
  65. Misheva M, Ilott NE, McCullagh JS. Recent advances and future directions in microbiome metabolomics. Curr Opin Endocr Metab Res. 2021;20:100283.
  66. Domenick TM, Gill EL, Vedam-Mai V, Yost RA. Mass spectrometry-based cellular metabolomics: current approaches, applications, and future directions. Anal Chem. 2020;93(1):546-66.
  67. Soni V, Bartelo N, Schweickart A, Chawla Y, Dutta A, Jain S. Future perspectives of metabolomics: gaps, planning, and recommendations. In: Metabolomics: Recent Advances and Future Applications. Cham: Springer International Publishing; 2023. p. 479-512.
Ahead of Print Subscription Review Article
Volume
Received July 24, 2024
Accepted August 17, 2024
Published August 17, 2024
Views: 51

Check Our other Platform for Workshops in the field of AI, Biotechnology & Nanotechnology.
Learn more
Check Out Platform for Webinars in the field of AI, Biotech. & Nanotech.
Learn more